Alimera Sciences: Addressing DME with Persistent Microdose Therapy (OIS@ASRS 2016)

Aerie Pharmaceuticals: Moving Beyond Glaucoma (OIS@ASRS 2016)Подробнее

Study Review: Continuous Microdosing Treatment DMEПодробнее

Ophthalmology Innovator Stories: What Is Alimera Sciences?Подробнее

Alimera Tackles IOP Questions of Iluvien Head On (OIS@AAO 2016)Подробнее

AAO DME in the Real WorldПодробнее

Alimera Sciences - OIS@AAO 2015Подробнее

New DME Hope: 1 implant, 36-monthsПодробнее

Alimera Sciences Reveals Details of Promising New Illuvien TrialПодробнее

SNN: Iluvien Procedure Helps Diabetics Regain VisionПодробнее

RET18 10 Section XIV Diabetes Role of Steroids in Diabetic Macular EdemaПодробнее

Amir Kashani, MD, PhD: Stem-Cell Based Therapy for Dry Age-Related Macular DegenerationПодробнее

New Treatments for Neuromyelitis Optica in the PipelineПодробнее

Carlos Pavesio - Ozurdex, Iluvien and RetisertПодробнее

OIS Podcast Episode #334: Early Stage Retina Drug Development FinancingПодробнее

Hemera Has Dry AMD in Its SightsПодробнее

Alimera Sees Black for 2018Подробнее

How to reduce the recurrence of edema with DME patients? | EYE NEWS TVПодробнее